Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Actinogen Medical ( (AU:ACW) ) has issued an announcement.
Actinogen Medical announced positive results from a Phase 2 trial of its drug Xanamem, presented at the American Psychiatric Association’s 2025 meeting. The trial demonstrated that a 10 mg dose of Xanamem significantly improves symptoms of moderate Major Depressive Disorder, validating its mechanism of controlling brain cortisol levels. These findings not only highlight Xanamem’s potential as an effective antidepressant with a unique mechanism of action but also support its use in ongoing trials for Alzheimer’s Disease. The promising safety profile and durability of Xanamem’s benefits position it as a competitive candidate in the antidepressant market, potentially benefiting patients with Alzheimer’s who also suffer from depression.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Their lead compound, Xanamem, is being developed as a treatment for Alzheimer’s Disease and Depression, with potential future applications in Fragile X Syndrome and other conditions. The company addresses substantial unmet medical needs by targeting cognitive dysfunction and behavioral abnormalities associated with these diseases.
YTD Price Performance: -12.00%
Average Trading Volume: 8,276,724
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$69.9M
For detailed information about ACW stock, go to TipRanks’ Stock Analysis page.